

RNS Number : 0414Z
CRISM Therapeutics Corporation
12 September 2025

12 September 2025



CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")

Notice of Interim Results and Presentation via Investor Meet Company

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, will announce its Interim Results for the six months ended 30 June 2025 on Monday 15 September 2025.

Following the results announcement, Andrew Webb, CEO of CRISM Therapeutics, will host a live presentation via Investor Meet Company on Tuesday 16 September 2025 at 12.00pm BST. The presentation will include Garth Cruickshank, Emeritus Professor of Neurosurgery at University of Birmingham and Queen Elizabeth Hospital Birmingham.

Professor Cruickshank, a member of CRISM's Scientific Advisory Board, will discuss the Company's upcoming Phase 2 trial of irinotecan-ChemoSeed in glioblastoma, including the early stage work leading up to the start of the Phase 2 trial.

The Investor Meet Company presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am BST on 15 September 2025 or at any time during the live presentation.

Investors can sign up, free of charge, to Investor Meet Company and add to meet CRISM Therapeutics via: <https://www.investormeetcompany.com/crism-therapeutics-corporation/register-investor>

Investors who already follow the Company on the Investor Meet Company platform will automatically be invited.

-Ends-

Enquiries:

Company
CRISM Therapeutics Corporation

Andrew Webb, CEO
Chris McConville, CSO
via Burson Buchanan

Nomad and Broker
S.P. Angel Corporate Finance LLP

Richard Morrison
Vadim Alexandre
Adam Cowl
+44 (0) 20 3470 0470

Financial PR
Burson Buchanan

Mark Court / Jamie Hooper
CRISM@buchanancomms.co.uk
+44 (0) 20 7466 5000

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local and sustained delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This ensures that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in Q1 2026.

For more information please visit: <https://www.crismtherapeutics.com/>

The Company's LEI is 213800XFW6MKVCHHPW88.

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORQFLFFEKLEBBE